Each ADS represents 10 ordinary shares
The Company s ordinary shares continue to trade on Euronext Amsterdam
No new shares issued in connection with the Nasdaq listing
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ( ADSs ) have been admitted for listing on the Nasdaq Global Market ( Nasdaq ) under the symbol PHAR and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company s ordinary shares of €0.01 nominal value ( Ordinary Shares ).
The United States Securities and Exchange Commission ( SEC ) has also declared effective the Company s registration statements on Form F-1 and Form F-6, each filed with the SEC.
Pharming Reports on Extraordinary General Meeting of Shareholders
LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
A recording of the webcast and the presentation slides from today s EGM are available on the Company s website: https://www.pharming.com/investors/shareholder-meetings
About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
(2)
Highlights:
First patient treated in second clinical trial globally investigating the use of RUCONEST to prevent severe SARS-CoV-2 infections in hospitalised patients with confirmed COVID-19
Planned expansion to multiple centres across the US
LEIDEN, The Netherlands, Dec. 10, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) today announced that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.